TScan Therapeutics's total assets for Q1 2025 were $332.71M, a decrease of -10.35% from the previous quarter. TCRX total liabilities were $122.51M for the fiscal quarter, a -5.87% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.